Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.59 |
| ▸ | BTK | Q06187 | 10/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18132001 | 0.87 | DYRK1A (0.50) | JAK2BTKDYRK1A | |
| SCHEMBL18131976 | 0.87 | JAK2 (0.46) | JAK2BTKDYRK1A | |
| SCHEMBL3617529 | 0.86 | JAK2 (0.59) | JAK2BTKPIM1PIM3DYRK1A | |
| SCHEMBL29523335 | 0.86 | JAK2 (0.59) | JAK2BTKPIM1PIM3DYRK1A | |
| SCHEMBL10476463 | 0.82 | JAK2 (0.45) | JAK2BTKDYRK1A | |
| SCHEMBL3612956 | 0.82 | NR4A2 (0.51) | JAK2PIM1PIM3 | |
| SCHEMBL18132112 | 0.81 | JAK2 (0.71) | JAK2JAK3 | |
| SCHEMBL3610664 | 0.81 | JAK2 (0.52) | JAK2JAK3 | |
| SCHEMBL18132129 | 0.81 | JAK2 (0.52) | JAK2JAK3 | |
| SCHEMBL18136510 | 0.81 | JAK2 (0.51) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280418-B1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-3280418-B1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| EP-3280418-A1 | AZACARBAZOLE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016164284-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016161570-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164284-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1954290-B1 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1954290-B1 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| WO-2007061764-A2 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | JAK2, JAK3, JAK1 | JAK2 1/4885BTK 37/4885PIM1 260/4885 |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | BTK, SYK, LYN | JAK2 6/4885BTK 1/4885PIM1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.